Amit Shah

Amit Shah is a seasoned pharmaceutical executive and entrepreneur with over two decades of experience scaling companies from early-stage development through successful exits. As a key leader at Bio-Pharm, Inc. from 2001-2018, he orchestrated the company’s transformation from a 10,000 sq ft private label manufacturer into a leading specialty pharmaceutical developer with 200,000+ sq ft of manufacturing and R&D facilities employing 150+ people. During his tenure, he led the successful development and FDA approval of multiple complex ANDA and 505(b)(2) products, ultimately delivering a strategic exit to Torrent Pharmaceuticals in 2018 that established their first U.S. manufacturing presence.

A serial investor and board leader, Amit is currently serving as Board Director of Marius Pharmaceuticals, guiding and driving the successful commercialization of an innovative FDA-approved NDA for oral testosterone therapy.

Amit’s operational expertise spans drug development, regulatory strategy, manufacturing scale-up, and commercial launch across multiple therapeutic areas. As an active investor in pharmaceutical and medical technology companies, Amit brings both operational leadership experience and investment acumen to healthcare innovation at 215 Capital. Amit’s ability to navigate complex regulatory pathways, scale manufacturing operations, and execute value-creating exits in the pharmaceutical sector make him particularly valuable for evaluating investment opportunities, supporting portfolio companies through critical development milestones, and providing strategic guidance on regulatory, manufacturing, and commercial strategies.